Catalyst Wire Dossier Catalyst Wire Dossier

Rifampicin (high-dose formulation for Hi-DoRi-3 therapy)

rifampicin
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Rifampicin (high-dose formulation for Hi-DoRi-3 therapy), covering 2020-07-24 to 2020-07-24. Get the full timeline:

Most recent: Clinical Trial Update: Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) [Phase 3]

See pricing